Every Form 4 that PLUS THERAPEUTICS, Inc. (PSTV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PSTV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PSTV filings page.
PLUS THERAPEUTICS, INC. director Kyle Guse exercised restricted stock units to acquire 922 shares of Common Stock at no cost. After the transaction, he directly holds 922 Common shares. A related RSU grant totaling 2,764 units remains outstanding and vests in four substantially equal quarterly installments beginning on July 1, 2026.
PLUS THERAPEUTICS director Ronald Asbury Andrews exercised equity awards, acquiring additional common stock through RSU vesting. On July 1, 2026, 922 Restricted Stock Units converted into 922 shares of common stock at a stated price of $0.00 per share as part of his compensation. Following the transaction, he directly holds 922 shares of common stock and 2,764 Restricted Stock Units that represent rights to receive the same number of shares, vesting in four substantially equal quarterly installments beginning on July 1, 2026.
PLUS THERAPEUTICS director An van Es-Johansson reported the vesting of 922 Restricted Stock Units (RSUs), which were converted into an equal number of shares of Common Stock at a price of $0.00 per share. Following this transaction, the reporting person directly holds 922 shares of Common Stock.
The RSU grant vests in four substantially equal quarterly installments beginning on July 1, 2026, meaning this filing reflects a compensation-related derivative exercise rather than an open-market purchase or sale, with no shares disposed of in the transaction.
PLUS THERAPEUTICS, INC. Chief Executive Officer Marc H. Hedrick reported routine equity compensation activity as Restricted Stock Units vested into Common Stock. On July 1, 2026, RSU vesting resulted in the acquisition of 16,439 shares of Common Stock at an exercise price of $0.00 per share. Following these conversions, he directly holds 34,431 shares of Common Stock and 163,650 RSUs, which represent contingent rights to receive an equal number of shares. The RSU grants vest in twelve substantially equal quarterly installments beginning on October 1, 2025, April 1, 2026, and July 1, 2026.
Plus Therapeutics director Howard Clowes exercised restricted stock units into common shares as part of equity compensation. On this Form 4, he acquired 922 shares of Plus Therapeutics common stock through the conversion of restricted stock units at a stated price of $0.00 per share.
Following the transaction, Clowes directly holds 1,981 shares of common stock and 2,764 restricted stock units. Each RSU represents a contingent right to receive one common share, with vesting in four substantially equal quarterly installments beginning on July 1, 2026. This filing reflects routine equity incentive vesting rather than an open-market stock purchase or sale.
PLUS THERAPEUTICS director Richard J. Hawkins reported a compensation-related equity transaction involving 922 shares. On July 1, 2026, 922 Restricted Stock Units (RSUs) vested, each RSU converting into one share of PLUS THERAPEUTICS common stock at a price of $0.00 per share.
The filing shows Hawkins directly holding 1,529 shares of common stock after the transaction, along with 2,764 RSUs that remain outstanding. According to the footnotes, this RSU grant vests in four substantially equal quarterly installments beginning on July 1, 2026, highlighting that this is a scheduled equity award rather than an open‑market trade.
PLUS THERAPEUTICS, INC. Chief Financial Officer Andrew John Hugh MacIntyre Sims reported equity compensation-related transactions in the company’s common stock. On July 1, 2026, he exercised or converted derivative awards into a total of 2,985 shares of common stock at a stated price of $0.0000 per share, reflecting non-cash vesting of awards.
The filing shows his direct holdings of common stock at 9,941 shares after one of the transactions, with 28,522 restricted stock units (RSUs) remaining after another. Footnotes state that each RSU represents a right to one common share and that the RSU grants vest in twelve substantially equal quarterly installments beginning on October 1, 2025, April 1, 2026, and July 1, 2026, respectively. These transactions appear to be part of scheduled RSU vesting rather than open-market buying or selling.
van Es-Johansson An reported acquisition or exercise transactions in this Form 4 filing.
PLUS THERAPEUTICS director An van Es-Johansson received new equity awards. On May 14, 2026, the director was granted options to buy 3,686 shares of common stock at $5.76 per share, expiring on May 14, 2036, vesting monthly over 12 months or fully at the 2027 Annual Stockholder Meeting. The director also received 3,686 restricted stock units, each representing one share, vesting in four equal quarterly installments starting July 1, 2026.
Plus Therapeutics director Richard J. Hawkins received new equity awards on May 14, 2026. He was granted stock options for 3,686 shares of common stock at an exercise price of $5.76 per share, expiring on May 14, 2036. He also received 3,686 Restricted Stock Units, each representing one share of common stock.
The RSUs vest in four equal quarterly installments starting on July 1, 2026. The options vest in substantially equal monthly increments over 12 months, and are scheduled to be fully vested at the company’s 2027 Annual Stockholder Meeting, subject to his continued service.
Plus Therapeutics director Kyle Guse reported receiving new equity compensation awards. He was granted stock options covering 3,686 shares of Common Stock at an exercise price of $5.76 per share, expiring on May 14, 2036. These options vest monthly over 12 months and will vest in full at the company’s 2027 Annual Stockholder Meeting, subject to continued service.
He was also granted 3,686 Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The RSUs vest in four equal quarterly installments, starting with one-quarter vesting on July 1, 2026, with the remainder vesting quarterly thereafter. The filing shows no open-market buys or sells, only grants classified as acquisitions.
PLUS THERAPEUTICS, INC. director Howard Clowes reported new equity-based compensation awards. He received a stock option covering 3,686 shares of common stock at an exercise price of $5.76 per share, expiring on May 14, 2036. These options vest in substantially equal monthly installments over 12 months and vest in full at the company’s 2027 annual stockholder meeting if he continues serving through each vesting date.
Clowes was also granted 3,686 Restricted Stock Units, each representing a contingent right to receive one share of common stock. The RSUs vest in four substantially equal quarterly installments, with one-quarter vesting on July 1, 2026 and the remainder vesting quarterly thereafter, subject to continued service. These are non-cash, compensation-related acquisitions rather than open-market share purchases or sales.
PLUS THERAPEUTICS, INC. director Ronald Asbury Andrews reported new equity compensation awards, not open‑market trades. He received stock options for 1,600 shares of Common Stock at an exercise price of $5.76 per share, expiring on May 14, 2036, and an additional option for 3,686 shares at the same exercise price and expiration date.
He also received 3,686 Restricted Stock Units, each representing one share of Common Stock. According to the footnotes, the RSUs vest in four equal quarterly installments starting on July 1, 2026, while one option grant vests monthly over 12 months (with full vesting by the company’s 2027 Annual Stockholder Meeting) and the other vests monthly over 24 months.
PLUS THERAPEUTICS, INC. reported that its Chief Financial Officer, Andrew John Hugh MacIntyre, received new equity awards. He was granted stock options for 3,443 shares of Common Stock at an exercise price of $5.7600 per share, expiring on May 14, 2036. These options vest in substantially equal 1/48th monthly installments over four years and also vest on a change of control as described in his employment agreement.
He also received 3,443 Restricted Stock Units, each representing a right to receive one share of Common Stock. The RSUs vest ratably in 1/12th increments over twelve quarters, starting July 1, 2026, with the remainder vesting quarterly, and his total RSU holdings increased to 30,055 units after this grant.
PLUS THERAPEUTICS, INC. reported that Chief Executive Officer Marc H. Hedrick received new equity-based compensation awards. He was granted options to buy 23,834 shares of common stock at an exercise price of $5.76 per share, along with 23,834 restricted stock units, each representing one share.
The restricted stock units vest in 12 equal quarterly installments, beginning on July 1, 2026
PLUS THERAPEUTICS, INC. granted Chief Development Officer Eric Joseph Daniels equity-based compensation. He received stock options covering 20,000 shares of Common Stock at an exercise price of $7.30 per share, expiring on April 19, 2036. One fourth of these options vest on April 20, 2027, with the remaining options vesting in substantially equal monthly installments over the following 36 months.
Daniels was also awarded 20,000 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock. One third of the RSUs vest on July 1, 2027, and the remaining RSUs vest ratably over the next eight quarters in substantially equal increments. These awards are compensation grants rather than open-market purchases or sales.
PLUS THERAPEUTICS Chief Financial Officer Andrew John Hugh MacIntyre Sims acquired shares through RSU vesting. On April 1, 2026, he exercised Restricted Stock Units to receive a total of 67,452 shares of Common Stock in two transactions of 38,323 and 29,129 shares at an exercise price of $0.00 per share.
Following these transactions, his direct holdings of Common Stock increased to 173,913 shares. Footnotes state that each Restricted Stock Unit represents a contingent right to receive one share of Common Stock and that the RSU grants vest in twelve substantially equal quarterly installments beginning on specified dates.
PLUS THERAPEUTICS, INC. Chief Executive Officer Marc H. Hedrick exercised restricted stock units into common shares in a compensation-related transaction. He acquired a total of 361,313 shares of Common Stock on April 1, 2026 through derivative exercises at a per-share price of $0.00.
The filing shows two RSU conversions of 159,681 and 201,632 units, each RSU representing a contingent right to one common share. Following these transactions, Hedrick directly holds 701,100 shares of Common Stock. The transactions involve no open-market purchases or sales and reflect the vesting and settlement of prior equity awards.
PLUS THERAPEUTICS, INC. reported that Chief Financial Officer Andrew John Hugh MacIntyre acquired equity awards consisting of restricted stock units and stock options. He received 349,542 Restricted Stock Units, each representing a contingent right to one share of common stock, and 349,541 stock options with a right to buy common stock.
The RSUs vest in substantially equal 1/12th increments over twelve quarters, beginning on April 1, 2026 with the remaining portions vesting quarterly thereafter. The options vest over four years in substantially equal 1/48th monthly increments on each monthly anniversary of grant and also vest upon a change of control in accordance with his employment agreement.
HEDRICK MARC H reported acquisition or exercise transactions in this Form 4 filing.
PLUS Therapeutics reported that Chief Executive Officer Marc H. Hedrick received new equity awards. He was granted 2,419,582 Restricted Stock Units, each representing one share of common stock, and 2,419,582 stock options with a right to buy common shares.
The RSUs vest in twelve equal quarterly installments, starting with the first 1/12th on April 1, 2026 and continuing quarterly thereafter. The stock options vest in 48 equal monthly installments over four years, and also vest upon a change of control as provided in his employment agreement.
Plus Therapeutics (PSTV) reported an insider purchase by its Chief Financial Officer. On 11/04/2025, the CFO acquired 20,000 shares of common stock at a weighted average price of $0.51, with individual trades executed between $0.504 and $0.509. Following the transaction, the reporting person beneficially owns 68,138 shares, held directly.
The filing notes the purchase details were made across multiple trades, and the reporting person will provide a breakdown of shares bought at each price within the stated range upon request.